> ABOUT US > Our History
- Technology transfer of the bispecific antibody drug OXTIMA to Navigator Medicine (USA) and Huadong Medicine (China)
- Signed MOU with LigaChem for strategic collaboration in ADC therapy development
- Presented pH-sensitive B7H3 ADC research results at the World ADC Conference
- Presented research on TGFβ SelecTrap and HLA-G ALiCE at SITC 2024
- Presented anti-CD39 antibody research results at AACR 2024
- Licensing of YBL-007 antibody sequence for Vaxcell-Bio CAR-T/NK application.
- Listed on KOSDAQ
- Technology transfer of an immuno-oncology candidate, co-developed with Wellmarker Bio, to a European biotech company
- Completed technology evaluation (Grade A, A) for KOSDAQ listing under the technology-special track
- Completed Phase 1/2a clinical trial of Acrixolimab (YBL-006)
- Raised KRW 8 billion in Pre-IPO funding
- Filed domestic patent for HLA-G monoclonal antibody
- Filed domestic patent related to TGF-β
- Registered U.S. patent for Acrixolimab (YBL-006) under the International Nonproprietary Name (INN)
- Signed technology transfer agreement with Pierre Fabre for YBL-003
- Awarded Outstanding Corporate Research Institute by the Ministry of Science and ICT
- Signed technology transfer agreement with Pyxis Oncology for YBL-001 (co-developed with LegoChem Biosciences) – Press Release
- Signed China-exclusive technology transfer agreement with 3D Medicines (3D MED) for YBL-013 – Press Release
- Signed joint R&D agreement with NeoImmuneTech for YBL-018 – Press Release
- Signed antibody information transfer agreement with ViroCure for YBL-006 and others – Press Release
- Signed antibody information transfer agreement with GI Innovation for YBL-006 and others – Press Release
- Initiated Phase 1 clinical trial of YBL-006 (in Korea, Australia, etc.)
- Registered U.S. patent for T-cell bispecific antibody platform (ALiCE)
- Received Jang Young-Shil Technology Innovation Award (Minister of Science and ICT Award)
- Raised KRW 20 billion in Series D funding
- Signed joint research agreement with LegoChem Biosciences for YBL-001
- Signed joint research agreement with HK inno.N for three bispecific antibody programs
- Raised KRW 15 billion through Series A and B funding rounds
- Raised KRW 1 billion in seed funding
- Certified as a venture company and a corporate-affiliated research institute
- Company founded